Stock 2511 HIGHTIDE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News HighTide Therapeutics, Inc.

Equities

2511

KYG4568L1023

Delayed Hong Kong S.E.
Other stock markets
 11:46:31 19/06/2024 am IST 		5-day change 1st Jan Change
3.93 HKD +6.79% Intraday chart for HighTide Therapeutics, Inc. -7.09% -69.68%
18/06 8,774,232 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024. CI
21/05 108,000,000 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2024. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
8,774,232 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.
CI
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...
EQ
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study
AQ
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
AQ
108,000,000 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2024.
CI
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator
MT
Hightide Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase IIb Clinical Trial Evaluating HTD1801
CI
HighTide Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HighTide Therapeutics, Inc. Announces Resignation of Mr. LI LI as A Non-Executive Director
CI
HighTide Therapeutics to Set Up New Plant in China Expansion Plans
MT
China's Curbs on Game Spending Pulls Down Hong Kong Stocks; One Out of Four Trading Debutants Drop at Close
MT
Hightide Therapeutics Gains 7% in Hong Kong Trading Debut
MT
HighTide Therapeutics, Inc. has completed an IPO in the amount of HKD 278.231 million.
CI
HighTide Therapeutics, Inc. announced that it has received CNY 100 million in funding from Cangzhou Chuangrong Equity Investment Fund Co., Ltd.
CI
HighTide Therapeutics, Inc. has filed an IPO in the amount of HKD 278.231 million.
CI
HighTide Therapeutics, Inc. Appoints Edmund Sim as Chief Financial Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2511 Stock
  4. News HighTide Therapeutics, Inc.